ICUD-EAU international consultation on bladder cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder

Maximilian Burger, Willem Oosterlinck, Badrinath Konety, Sam Chang, Sigurdur Gudjonsson, Raj Pruthi, Mark Soloway, Eduardo Solsona, Paul Sved, Marko Babjuk, Maurizio A. Brausi, Christopher Cheng, Eva Comperat, Colin Dinney, Wolfgang Otto, Jay Shah, Joachim Thürof, J. Alfred Witjes

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. Conclusions: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.

Original languageEnglish
Pages (from-to)36-44
Number of pages9
JournalEuropean Urology
Volume63
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Referral and Consultation
Carcinoma
Carcinoma in Situ
Cystectomy
Therapeutics
Retrospective Studies
Prospective Studies
Recurrence
Drug Therapy

Keywords

  • Bacillus Calmette-Guérin (BCG)
  • Bladder cancer
  • Cystoscopy
  • Diagnosis
  • Guidelines
  • Intravesical chemotherapy
  • Prognosis
  • Transurethral resection (TUR)

ASJC Scopus subject areas

  • Urology

Cite this

Burger, M., Oosterlinck, W., Konety, B., Chang, S., Gudjonsson, S., Pruthi, R., ... Witjes, J. A. (2013). ICUD-EAU international consultation on bladder cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. European Urology, 63(1), 36-44. https://doi.org/10.1016/j.eururo.2012.08.061

ICUD-EAU international consultation on bladder cancer 2012 : Non-muscle-invasive urothelial carcinoma of the bladder. / Burger, Maximilian; Oosterlinck, Willem; Konety, Badrinath; Chang, Sam; Gudjonsson, Sigurdur; Pruthi, Raj; Soloway, Mark; Solsona, Eduardo; Sved, Paul; Babjuk, Marko; Brausi, Maurizio A.; Cheng, Christopher; Comperat, Eva; Dinney, Colin; Otto, Wolfgang; Shah, Jay; Thürof, Joachim; Witjes, J. Alfred.

In: European Urology, Vol. 63, No. 1, 01.01.2013, p. 36-44.

Research output: Contribution to journalArticle

Burger, M, Oosterlinck, W, Konety, B, Chang, S, Gudjonsson, S, Pruthi, R, Soloway, M, Solsona, E, Sved, P, Babjuk, M, Brausi, MA, Cheng, C, Comperat, E, Dinney, C, Otto, W, Shah, J, Thürof, J & Witjes, JA 2013, 'ICUD-EAU international consultation on bladder cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder', European Urology, vol. 63, no. 1, pp. 36-44. https://doi.org/10.1016/j.eururo.2012.08.061
Burger, Maximilian ; Oosterlinck, Willem ; Konety, Badrinath ; Chang, Sam ; Gudjonsson, Sigurdur ; Pruthi, Raj ; Soloway, Mark ; Solsona, Eduardo ; Sved, Paul ; Babjuk, Marko ; Brausi, Maurizio A. ; Cheng, Christopher ; Comperat, Eva ; Dinney, Colin ; Otto, Wolfgang ; Shah, Jay ; Thürof, Joachim ; Witjes, J. Alfred. / ICUD-EAU international consultation on bladder cancer 2012 : Non-muscle-invasive urothelial carcinoma of the bladder. In: European Urology. 2013 ; Vol. 63, No. 1. pp. 36-44.
@article{4f91146beaca4e8bb8a8c624cce7a923,
title = "ICUD-EAU international consultation on bladder cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder",
abstract = "Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. Conclusions: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.",
keywords = "Bacillus Calmette-Gu{\'e}rin (BCG), Bladder cancer, Cystoscopy, Diagnosis, Guidelines, Intravesical chemotherapy, Prognosis, Transurethral resection (TUR)",
author = "Maximilian Burger and Willem Oosterlinck and Badrinath Konety and Sam Chang and Sigurdur Gudjonsson and Raj Pruthi and Mark Soloway and Eduardo Solsona and Paul Sved and Marko Babjuk and Brausi, {Maurizio A.} and Christopher Cheng and Eva Comperat and Colin Dinney and Wolfgang Otto and Jay Shah and Joachim Th{\"u}rof and Witjes, {J. Alfred}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.eururo.2012.08.061",
language = "English",
volume = "63",
pages = "36--44",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - ICUD-EAU international consultation on bladder cancer 2012

T2 - Non-muscle-invasive urothelial carcinoma of the bladder

AU - Burger, Maximilian

AU - Oosterlinck, Willem

AU - Konety, Badrinath

AU - Chang, Sam

AU - Gudjonsson, Sigurdur

AU - Pruthi, Raj

AU - Soloway, Mark

AU - Solsona, Eduardo

AU - Sved, Paul

AU - Babjuk, Marko

AU - Brausi, Maurizio A.

AU - Cheng, Christopher

AU - Comperat, Eva

AU - Dinney, Colin

AU - Otto, Wolfgang

AU - Shah, Jay

AU - Thürof, Joachim

AU - Witjes, J. Alfred

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. Conclusions: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.

AB - Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. Conclusions: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.

KW - Bacillus Calmette-Guérin (BCG)

KW - Bladder cancer

KW - Cystoscopy

KW - Diagnosis

KW - Guidelines

KW - Intravesical chemotherapy

KW - Prognosis

KW - Transurethral resection (TUR)

UR - http://www.scopus.com/inward/record.url?scp=84870477356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870477356&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.08.061

DO - 10.1016/j.eururo.2012.08.061

M3 - Article

C2 - 22981672

AN - SCOPUS:84870477356

VL - 63

SP - 36

EP - 44

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -